Expression data from rat pituitary adenoma cells

Cabergoline (CAB) and bromocriptine (BRC) as first-line drug are recommended for treating patients with prolactinoma. Nonetheless, patients present with the differences of effective to CAB and BRC. The sensitivities of patients to the two drugs were different. We used microarrays to detail the global programme of gene expression underlying in treatment of CAB and BRC, and identified distinct classes of up-regulated genes during this process. Rat pituitary adenoma cells were treated with CAB and BRC for RNA extraction and high throughput sequencing on Affymetrix GeneChip® Rat Genome 230 2.0 Array . The differential gene expression between the groups was analyzed. The groups as following：1. MMQ 2.MB (MMQ+BRC) 3.GH3 4.GC(GH3+CAB) 5.GB(GH3+BRC) 6.GCB(GH3+BRC+CAB) 7.MC(MMQ+CAB) 8.MCB(MMQ+CAB+BRC)

卡麦角林（Cabergoline, CAB）与溴隐亭（bromocriptine, BRC）为催乳素瘤患者的一线推荐治疗药物。然而，不同患者对CAB与BRC的治疗敏感性存在显著差异。本研究通过微阵列技术，详细解析了CAB与BRC治疗过程中全局基因表达的调控特征，并筛选得到该过程中不同类别的上调基因。我们将大鼠垂体腺瘤细胞分别经CAB、BRC单独或联合处理后提取RNA，采用Affymetrix GeneChip® 大鼠基因组230 2.0阵列（Affymetrix GeneChip® Rat Genome 230 2.0 Array）进行高通量测序。随后对各组间的差异基因表达情况展开分析，实验分组设置如下：1. MMQ组；2. MB组（MMQ+BRC）；3. GH3组；4. GC组（GH3+CAB）；5. GB组（GH3+BRC）；6. GCB组（GH3+BRC+CAB）；7. MC组（MMQ+CAB）；8. MCB组（MMQ+CAB+BRC）